Boston Scientific Corporation

(New York Stock Exchange)
Back to all articles
Slightly Bearish -15

Boston Scientific stock holds steady as analysts weigh cyberattack impact

AI-generated analysis

πŸ“‰ Boston Scientific shares closed at USD 43.41 on September 18, 2026, trading roughly 63.6% below the consensus analyst price target of USD 71.04.

πŸ›‘οΈ A recent cyberattack is weighing on analyst sentiment, prompting Citi to downgrade the stock while other houses maintain Buy ratings with trimmed near-term forecasts.

πŸ’° The company holds a market capitalization of approximately USD 62.91 billion and trades at a trailing price-earnings ratio of 17.57.

πŸ“Š Analyst consensus consists of 23 Buy, 6 Hold, and 2 Sell recommendations, indicating a Moderate Buy rating overall.

πŸ“ˆ Independent valuation analysis suggests the stock may be undervalued by roughly 56% relative to fair value estimates based on cash flows.

πŸ₯ Boston Scientific operates in the Health Care / Medical Devices sector with shares currently hovering near their 52-week low of USD 42.20.

Bullish Signals
  • Independent valuation analysis suggests the stock could be trading at a discount to intrinsic value, potentially undervalued by approximately 56% relative to fair value estimates based on cash flows.
  • Despite recent headwinds, the sell-side consensus maintains a Moderate Buy rating with an average price target of USD 71.04, implying significant upside potential from current levels.
Risk Factors
  • Citi downgraded the stock citing intensifying competition in the medical device markets and lingering effects from a recent cyberattack as key risk factors.
  • Analysts are reassessing near-term forecasts due to operational disruption caused by the cyberattack, leading some to trim their price targets despite maintaining Buy ratings.
  • The stock is trading near its 52-week low of USD 42.20, reflecting market concerns about the severity of the cyberattack and competitive pressures.
Full Analysis
Boston Scientific stock closed at USD 43.41 on September 18, 2026, trading significantly below the consensus analyst price target of USD 71.04. The company's shares are currently positioned near their 52-week low of USD 42.20, reflecting market caution regarding competitive pressures and the lingering fallout from a recent cyberattack that has impacted operational assessments. Analyst sentiment remains divided on the severity of the cyberattack incident. While Citi downgraded the stock citing intensifying competition and the security breach as key risk factors, other analysts maintain Buy ratings, viewing the cyberattack impact as short-lived despite trimming near-term forecasts to account for disruption. This divergence highlights a classic risk-reward debate among investors regarding the company's long-term trajectory versus immediate operational risks. Valuation metrics suggest Boston Scientific carries a trailing price-earnings ratio of 17.57 with a market capitalization of approximately USD 62.91 billion. Independent valuation models indicate the stock could be trading at a discount to intrinsic value, potentially undervalued by around 56% relative to fair value estimates based on cash flows and historical performance track records.